M&A Roundtable Q4 2025 – Reflections and Predictions
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
Andrew Gigax, Head of European Pharma Services M&A at William Blair
Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting
Sabina Ouimet Storrs, Principal at GHO Capital Partners
Jason Foss, Head of Corporate Development at Bora Pharmaceuticals
Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including:
How market stabilisation has been overtaken by the need for adaptation in times of uncertainty
Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency
The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments
Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services
Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far
The shifts and trends that could reshape pharma services in the years ahead
Molecule to Market is sponsored by Bora Pharma, Charles River and Lead Candidate, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!
--------
1:13:23
--------
1:13:23
From Pharma to CRO entrepreneur
In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest.
The conversation covers:
Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure
The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business
How a major strategic partnership transformed the company’s trajectory and why Jean sees partnerships as a competitive weapon
Riding the tailwind of the FDA’s move away from animal testing and offering something game-changing in the CMC and GMP space
The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation
Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application.
Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.
Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!
--------
49:02
--------
49:02
The CEO leading Ensera's evolution
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Anderson, Chief Executive Officer at Ensera.
Your host, Raman Sehgal, speaks with Jason about the pharmaceutical and biotechnology supply chain, covering:
Why he chose BASF over law school, and why McKinsey ultimately was not for him
Moving from corporate life into a venture-backed polymer technology start-up before a major exit
The search for a PE-backed specialty manufacturing role that led him to Ensera (formerly SteriPack)
The importance of appreciating local knowledge when entering new markets
Similarities and differences between outsourced services in pharma and medical devices
How today’s changes, pain, and uncertainty in the markets are creating opportunity
Jason Anderson is CEO of Ensera (formerly SteriPack), a global contract design and manufacturing organization serving the pharmaceutical and medical device industries. He has led the company through a period of significant growth and change, including the integration of new design and product development capabilities with Ensera’s core manufacturing services, and the launch of the new Ensera trading name.
Prior to Ensera, Jason held global business unit leadership roles at DJO/Enovis and at Saint-Gobain, overseeing businesses ranging from finished medical devices to customized, high-value components for biopharma and medical device industries. Earlier in his career, he held leadership roles at pre-revenue polymer technology start-up Novomer, at McKinsey and Company, and at BASF.
Jason has lived and worked in North America, Asia, and Europe. He holds a BS in Chemical Engineering from the University of Oklahoma and an MBA from Harvard Business School.
Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!
--------
55:43
--------
55:43
CPHI 2025 wrap-up
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with our host Raman Sehgal, who discusses the themes and vibe of CPHI 2025 in Frankfurt.
Molecule to Market is also sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
--------
28:51
--------
28:51
20 years of CPHI - Veterans Guide
In this episode of Molecule to Market, you’ll hear wily old wisdom, golden nuggets and invaluable insider tips about CPHI. The nuanced stuff from Veterans of CPHIs gone by you’ll never find in a generic AI-written playbook. The show features:
James West, Managing Director, Bourne Partners
Arul Ramadurai, CCO at Axplora
Christine Fuerst, Director Key Account Management Europe, Vetter Pharma International GmbH
Dan Stanton, leading pharma/biopharma industry journalist
Jeremy Drummond PhD, retired VP Sales and Marketing Exec.
Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!
About Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization.
Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider. is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
https://moleculetomarketpod.com
UK